Prostate Cancer Biomarkers and Therapeutics
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 2599
Special Issue Editor
Special Issue Information
Dear Colleagues,
Prostate cancer is one of the most common cancers in men worldwide. Although the five-year survival rate is 98%, the disease presents remarkable heterogeneity in its progression and seems to be influenced not only by genetics and family history but also by race, diet and lifestyle. Since early detection is key to increased survival, significant developments have occurred recently with the advent of biomarkers such as PSA, PCA3, TMPRSS2-ERG fusion, etc. However, many of the screening biomarkers suffer from poor specificity and sensitivity and do not accurately predict survival or treatment outcomes. Thus, the development of new biomarkers and/or strategies for the incorporation of existing biomarkers with machine learning technology is urgently needed for accurate personalized diagnosis and treatment outcome predictions. On the treatment front, there has been an increase in the availability of new therapies, including targeted, combinatorial and immunotherapies. Although the mainstay of the therapy is targeting the androgen signaling axis, new strategies have recently been developed that are improving radiation and chemotherapy outcomes through the utilization of immune-targeted radiation therapy and personalized combinatorial chemo and immunotherapy. This Special Issue aims to consolidate recent advancements in prostate cancer biomarkers and therapeutics, which will be of interest to both researchers and clinicians.
Dr. Kamlesh Kumar Yadav
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- biomarkers
- therapeutics
- chemotherapy
- immunotherapy
- radiation therapy
- machine learning
